RECRUITINGOBSERVATIONAL
Purinergic Signaling and the Postmenopausal Heart
PGC-1, Purines and the Postmenopausal Heart
About This Trial
There is an increased risk of diastolic heart failure in post menopausal women. Estrogen plays a positive role in regulating molecular pathways in heart remodeling. Such pathways may work through purinergic signaling and its downstream effects on the heart's mitochondrial metabolism and angiogenic response to stress. Loss of estrogen functionality in post menopausal women may account for the increased risk of diastolic heart failure. The investigators will explore said pathways using cardiac tissue obtained from patients undergoing cardiac surgery.
Who May Be Eligible (Plain English)
Who May Qualify:
- Patients undergoing cardiac surgery under cardiopulmonary bypass.
Who Should NOT Join This Trial:
- Refusal to participate
- Emergency surgery
- Pre-existing heart block
- Preexisting atrial fibrillation
- Redo surgery
- Estrogen or hormone replacement therapy
- History of chronic heart failure
- History of major kidney disease
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Patients undergoing cardiac surgery under cardiopulmonary bypass.
Exclusion Criteria:
* Refusal to participate
* Emergency surgery
* Pre-existing heart block
* Preexisting atrial fibrillation
* Redo surgery
* Estrogen or hormone replacement therapy
* History of chronic heart failure
* History of major kidney disease
Treatments Being Tested
OTHER
Gender
Differences between men and women will be observed
Locations (1)
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States